The AACR’s network of partnerships yielded several new funding opportunities in 2019:
grants were awarded in 2019 to meritorious scientists from 40 institutions to support groundbreaking research in all areas of cancer science.
applications were evaluated for AACR grants in 2019; applicants were from the United States and 21 other countries.
Amount of research grant funding awarded to 36 postdoctoral and clinical fellows to boost their career development and sustain the next generation of cancer scientists.
Amount awarded to independent investigators at all career levels—including young investigators, mid-career researchers, and established scientists—to support groundbreaking cancer science.
Expert scientists served on 18 scientific review committees to select the 2019 grant recipients through a rigorous peer-review process. The AACR is a trusted administrator of research grants, providing expert peer review that is fair, rigorous, transparent, and timely.
The strong leadership of SU2C’s Scientific Advisory Committee (SAC) is the key to the success of its dynamic funding models. As SU2C’s Scientific Partner, the AACR works to ensure that the SAC consists of the greatest minds in cancer research. In 2019, SU2C benefited from the bold vision of three new SAC vice-chairs: Elizabeth H. Blackburn, PhD, FAACR, a Nobel Laureate, Fellow of the AACR Academy, and AACR past president; Raymond N. DuBois, MD, PhD, FAACR, a Fellow of the AACR Academy and AACR past president; and Lee J. Helman, MD. These new members joined chair Phillip A. Sharp, PhD, FAACR, and vice-chairs Arnold J. Levine, PhD, FAACR, and William G. Nelson, MD, PhD, on this vital committee.
The new vice-chairs, who began their terms in the fall of 2018, were supported in their efforts by two new SAC members appointed in June. John D. Carpten, PhD—who also served as program chair for the AACR Annual Meeting 2019—is director of the Institute of Translational Genomics at the Keck School of Medicine of the University of Southern California. He joined the SAC while continuing to serve on SU2C’s committee on health equity in cancer clinical trials. Dr. Carpten was joined by Roderic I. Pettigrew, PhD, MD, chief executive officer of Engineering Health and executive dean for Engineering Medicine at Texas A&M University. Previously, Dr. Pettigrew was the founding director of the U.S. National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH).
Team science is at the core of SU2C’s mission. With oversight from the AACR, SU2C launched several new research teams in 2019 to address some of the greatest challenges in cancer research:
Through a strategic partnership with the Lustgarten Foundation, SU2C formed the Pancreatic Cancer Collective (PCC) in the spring of 2018 in a focused effort to improve outcomes for a disease with a current five-year survival rate of 8 percent. With the support of the AACR, SU2C’s Scientific Partner, the collective took bold steps toward that goal in 2019:
SU2C research teams bring together leading scientists to work together to solve key problems in cancer research. The Phillip A. Sharp Innovation in Collaboration Awards encourage these leaders to identify unique approaches to these problems and form new partnerships to pursue them. Named for Phillip A. Sharp, PhD, FAACR, chair of the SU2C Scientific Advisory Committee, the awards provide these new teams with grants of up to $250,000 to foster these promising collaborations. In May, SU2C announced the launch of five new projects with the potential to accelerate progress for the benefit of cancer patients: